PBYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Puma Biotechnology Inc (PBYI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show some bullish momentum, but the lack of positive catalysts, insider and hedge fund selling trends, and declining financial performance make this stock less attractive for long-term investment. Holding off for now is recommended.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.034, indicating upward momentum. RSI is neutral at 55.841, suggesting no overbought or oversold conditions. Key resistance levels are R1: 6.429 and R2: 6.588, with support at S1: 5.913 and S2: 5.754.
The stock's MACD and moving averages indicate short-term bullish momentum. Additionally, the stock has a 70% chance to increase by 0.65% in the next day.
Hedge funds and insiders are selling significantly, with insider selling up 230.93% in the last month and hedge fund selling up 203.10% in the last quarter. No recent news or congress trading data is available. The stock has a 70% chance of declining by -7.35% in the next week and -3.73% in the next month.
In Q4 2025, revenue increased by 27.72% YoY to $75,453,000. However, net income dropped by -30.39% YoY to $13,438,000, EPS declined by -33.33% YoY to 0.26, and gross margin fell by -9.28% YoY to 69.35%. These trends indicate declining profitability despite revenue growth.
No recent analyst rating or price target changes are available.
